-
Mashup Score: 1
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis. @ash_hematology #ASH24 #hematology https://t.co/LEW55rJn84
-
-
Mashup Score: 7
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis @IcahnMountSinai @MountSinaiNYC @ASH_hematology #ASH24 #hematology https://t.co/Yt29oVL3YY
-
-
Mashup Score: 2
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis. @ash_hematology #ASH24 #hematology https://t.co/LEW55rJn84
-
-
Mashup Score: 4A Final Chat with Our Clinician-Guides for ASH 2024 - 5 day(s) ago
Dr. Inas Abuali talks with Dr. Anjali Sharathkumar and Dr. Michael Williams about the major clinical takeaways from ASH 2024.
Source: cdn.jwplayer.comCategories: General Medicine News, General HCPsTweet-
Did you miss #ASH24? @inas_md chats with Dr. Anjali Sharathkumar and Dr. Michael Williams about the major clinical takeaways from the #hematology conference. https://t.co/Fl5NdYUrEc https://t.co/OgqIujFpbS
-
-
Mashup Score: 2Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis - 12 day(s) ago
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis. @ash_hematology #ASH24 #hematology https://t.co/LEW55rJn84
-
-
Mashup Score: 3High5 Oncology TV: ASH 2024 - 12 day(s) ago
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreiche
Source: high5oncology.tvCategories: General Medicine News, Hematologists1Tweet-
RT @high5md: Our coverage of #ASH24 is live! https://t.co/grtaVGiBj3 Discover all new study results on #hematology now, reported by expert…
-
-
Mashup Score: 6
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis @IcahnMountSinai @MountSinaiNYC @ASH_hematology #ASH24 #hematology https://t.co/Yt29oVL3YY
-
-
Mashup Score: 0ASH 2024 Preview for Integrative Care: The Show and After Show - 18 day(s) ago
CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
#ASH24 is set to shape the future of cancer care. Click here 👉 https://t.co/AJzls1UiJl to watch an exclusive episode of The Show and After-Show where we highlight news coming out of San Diego and share recommendations of what you can see and do while you’re in town. #hematology https://t.co/fv0d9yL6U3
-
-
Mashup Score: 1ASH 2024 Preview for Integrative Care: The Show and After Show - 20 day(s) ago
CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
#ASH24 is set to shape the future of cancer care. Click here 👉 https://t.co/AJzls1UiJl to watch an exclusive episode of The Show and After-Show where we highlight news coming out of San Diego and share recommendations of what you can see and do while you’re in town. #hematology https://t.co/fv0d9yL6U3
-
Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis @IcahnMountSinai @MountSinaiNYC @ASH_hematology #ASH24 #hematology https://t.co/Yt29oVL3YY